Illustration of immune cells weakened by cancer treatment, impacting cancer therapy.

Pazopanib's Impact: Can Cancer Treatment Affect Immunotherapy?

Samir D’Costa monogram
Samir D’Costa in Health & Wellness October 2026 • 4 min read.

"Research reveals how a common cancer drug may alter immune cell function, potentially impacting the effectiveness of personalized cancer vaccines."


Personalized medicine is rapidly advancing, especially in cancer treatment. One promising avenue is the development of dendritic cell (DC)-based vaccines, tailored to an individual's cancer profile. These vaccines harness the power of the patient's own immune system to fight the disease.

Monocytes, a type of white blood cell, are often used to create these personalized DC vaccines. The process involves isolating monocytes from the patient's blood, transforming them into dendritic cells in the lab, and then "charging" these DCs with tumor-specific antigens. The goal is to create a potent vaccine that stimulates the patient's immune system to target and destroy cancer cells.

However, a new study raises concerns about whether certain cancer treatments might compromise the effectiveness of this approach. Specifically, the research investigates how pazopanib, a tyrosine kinase inhibitor (TKI) commonly used to treat various cancers, affects the immunostimulatory properties of monocytes and, consequently, the potential of DC-based vaccines.

AI Search Multiple angles on this topic

A Century of Immunotherapy and Pazopanib’s Development

Cancer Research Institute describes cancer immunotherapy as a journey spanning more than 100 years, from early theories and experiments to modern treatments, shaped by pioneering research and Nobel Prize–winning discoveries. Its 2025 report likewise surveys more than a century of observations and breakthroughs. Separately, a technical guide traces pazopanib (Votrient®) from initial screening through development and approval, including its preclinical validation and pivotal clinical trials. The supplied sources do not establish a specific historical connection between the broader immunotherapy milestones and pazopanib’s development.

How Pazopanib Impacts Immune Cell Function

Illustration of immune cells weakened by cancer treatment, impacting cancer therapy.

The study, presented at the Annals of Oncology, explored the impact of pazopanib on monocytes derived from patients with metastatic renal cancer. Researchers compared monocytes from pazopanib-treated patients to those from a control group, focusing on how these cells responded to stimulation.

The key findings revolve around the observation that pazopanib appears to alter the characteristics of monocytes, specifically reducing their ability to stimulate an immune response. This was evidenced by several factors:

  • Reduced Co-Stimulatory Molecule Expression: The monocytes from pazopanib-treated patients showed diminished expression of key molecules needed to activate other immune cells.
  • Impaired IL-12 Production: IL-12 is a crucial cytokine that promotes a strong anti-cancer immune response. Pazopanib-exposed monocytes produced less of it.
  • Diminished T-Lymphocyte Stimulation: The monocytes were less effective at activating T-lymphocytes, a critical component of the immune system's ability to kill cancer cells.
  • Increased Expression of CD64 and ILT3: Pazopanib-treated monocytes exhibited higher levels of CD64 and ILT3, molecules associated with immune suppression.
  • Downregulation of HLA-Dr: Researchers found that pazopanib-treated monocytes exhibited lower capacity to upregulate HLA-Dr upon LPS stimulation.
AI Search Multiple angles on this topic

Recent Reviews and Pazopanib-Associated Changes

A 2019 study of dendritic-cell (DC) vaccines in pediatric patients with advanced sarcoma and neuroblastoma reports that vaccine-manufacturing outcomes varied in both DC yield and immunostimulatory properties. A 2025 review presents a comprehensive overview of current cancer immunotherapy approaches. In a 2026 report, pazopanib is described as inducing temporally structured remodeling of circulating extracellular vesicles: immune- and progenitor-related markers rose transiently at three months, while platelet-related markers showed biphasic dynamics. The listed material describes these findings but does not establish how they affect immunotherapy outcomes.

Evidence on Cell Proportions and Leukapheresis

A 1999 study found that the median proportion of blood dendritic cells in HIV-positive patients with plasma viral loads above 200 copies/ml was 0.2%, compared with 0.4% among patients with undetectable viral load and 0.4% in controls (P = 0.02). A separate study reports that mononuclear-cell leukapheresis appears to affect the proportion of monocyte-like cells in the lung, but found no evidence of a clinically important pro-inflammatory effect there. These studies address different populations and procedures; the supplied sources do not directly compare pazopanib with immunotherapy.

These changes suggest that pazopanib might be interfering with the normal function of monocytes, making them less capable of effectively initiating an anti-cancer immune response when used in DC-based vaccines.

Implications for Future Immunotherapy Strategies

This research highlights the importance of considering the potential impact of other cancer treatments on the effectiveness of immunotherapies. While pazopanib is a valuable tool in fighting cancer, its effects on immune cell function may need to be carefully considered when designing personalized DC-based vaccines.

AI Search Multiple angles on this topic

Pazopanib, Immunotherapy, and the Limits of Available Evidence

The supplied review snippet describes advanced soft tissue sarcoma as rare and heterogeneous and says better therapeutic strategies are needed; it notes that pazopanib, a widely used second-line treatment, has been suggested to have immunomodulatory effects. A separate guide says publicly available direct preclinical studies of pazopanib combined with immune checkpoint inhibitors in mice are limited, while describing its analysis of pazopanib alone and in immunotherapy combinations in murine models. Another source presents pazopanib as a possible option for frail or elderly patients considered unsuitable for immunotherapy, citing flexible dosing and an acceptable safety profile. Taken together, these sources raise possible treatment and research considerations but do not establish that pazopanib improves immunotherapy outcomes.

Persistent Challenges in Cancer Immunotherapy

A review of the current cancer immunotherapy landscape identifies resistance, variability in patient response, and the need for better biomarkers as challenges limiting widespread success. A 2024 Journal for ImmunoTherapy of Cancer review series aims to describe the field’s current state, address pressing challenges, and identify opportunities for high clinical impact across scientific, clinical, and regulatory areas. A separate review characterizes cancer immunotherapy as a growing field that modulates the immune system to destroy tumor cells and can produce durable antitumor immune responses. The supplied sources discuss broad field-level challenges, not pazopanib-specific effects on immunotherapy.

Real-World Pazopanib Use and Treatment Sequencing

A real-world study examined pazopanib use across a diverse group of malignancies using an electronic database and identified 123 eligible cases in the Northern California Kaiser Permanente Cancer Registry from January 2011 through October 2018. Separate 2019 reports describe real-world clinical outcomes for pazopanib given immediately after immunotherapy discontinuation in advanced renal cell carcinoma. The supplied snippets identify the population and treatment sequence but do not provide outcome figures, so they do not establish how effective or tolerable that sequence was.

Future research should focus on strategies to mitigate the negative effects of pazopanib on monocytes or to identify alternative approaches for creating effective DC vaccines in patients receiving this drug. It may also be beneficial to assess the timing of immunotherapy in relation to TKI treatment to optimize immune responses.

Ultimately, a deeper understanding of the interplay between targeted therapies and the immune system will be crucial for maximizing the potential of personalized cancer treatments.

Pazopanib's effects depend on the immune-cell setting

In the cited DC work, pazopanib was associated with signs of stronger DC maturation and T-cell activity, rather than uniformly weakened immune function. This differs from evidence about patients whose prior treatment interfered with monocyte biology, where manufactured DC vaccines had reduced IL-12 production and weaker immunostimulatory properties. These findings concern different cell settings and do not establish a single, consistent effect of pazopanib on vaccine performance.[1] [2]

The reported pathway result offers a possible explanation for the DC findings: pazopanib inhibited Erk/β-catenin signaling, which the authors suggested might be involved in increased DC activation. It does not establish that this pathway explains the findings in harvested monocytes.[1] [2]

DC findings beside other vaccine and kinase-inhibitor evidence

In pediatric sarcoma and neuroblastoma vaccine manufacturing, 30% of products did not meet medicinal-product specifications and were not released. This describes a production constraint in that patient group, not an outcome attributable to pazopanib.[2]

The same pediatric source reports below-average donor T-cell stimulation in six of seven cases with G-CSF exposure before monocyte harvest, with lower stimulation as exposure intensity increased. That comparison concerns G-CSF, so it cannot establish that pazopanib has the same association.[2]

A review describes kinase inhibitors as capable of either cooperating with immunotherapy or impairing host immune defense. This broader account is consistent with immune effects varying by drug and context; it does not resolve pazopanib’s effect on DC vaccines.[3]

What remains unclear about pazopanib and DC vaccines

  • Which treatments that interfere with monocyte biology account for the reduced IL-12 production and weaker function observed after treatment before monocyte harvest? The reported association does not identify pazopanib as the cause.[2]

Sources

  1. TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway. (pubmed.ncbi.nlm.nih.gov, 2018)
  2. Dendritic Cell-Based Immunotherapy in Advanced Sarcoma and Neuroblastoma Pediatric Patients: Anti-cancer Treatment Preceding Monocyte Harvest Impairs the Immunostimulatory and Antigen-Presenting Behav (www.frontiersin.org)
  3. Kinase Inhibitors’ Effects on Innate Immunity in Solid Cancers (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1093/annonc/mdw525.18, Alternate LINK

Title: Tki Pazopanib Impaires Immunostimulatory Properties Of Monocytes: Implication For Monocyte-Derived Dc-Based Anti-Cancer Vaccine Preparation

Subject: Oncology

Journal: Annals of Oncology

Publisher: Elsevier BV

Authors: L. Zdrazilova Dubska, L. Fedorova, K. Pilatova, P. Mudry, E. Hlavackova, E. Matoulkova, L. Flajsarova, R. Demlova, D. Valik, J. Sterba

Published: 2016-11-01

Everything You Need To Know

1

What is Pazopanib and why is it important in this context?

Pazopanib is a tyrosine kinase inhibitor (TKI) used in cancer treatment. It works by targeting and inhibiting specific enzymes that promote cancer cell growth and survival. Its significance lies in its ability to alter the function of immune cells, specifically monocytes. The implications of pazopanib include a potential reduction in the effectiveness of DC-based anti-cancer vaccines, which rely on the immune-stimulating properties of monocytes.

2

What are monocytes and why are they significant in this study?

Monocytes are a type of white blood cell that plays a crucial role in the immune system. They can be transformed into dendritic cells (DCs) in the lab, which are then used in personalized DC-based vaccines. The study suggests that Pazopanib exposure can alter monocytes characteristics, reducing their ability to stimulate an immune response. The implications of altered monocyte function are that they may be less effective in activating T-lymphocytes, a critical component of the immune system's ability to kill cancer cells.

3

How do dendritic cell (DC)-based vaccines work, and what is their significance?

Dendritic cell (DC)-based vaccines are a form of immunotherapy designed to stimulate a patient's immune system to fight cancer. Monocytes are transformed into DCs in a lab, 'charged' with tumor-specific antigens, and administered to the patient. The key finding suggests that pazopanib may reduce the efficacy of these vaccines by impairing the immunostimulatory properties of monocytes. The implications mean these vaccines might not be as effective in patients undergoing Pazopanib treatment, potentially requiring adjustments to treatment strategies.

4

What specific changes did the study find in monocytes treated with Pazopanib?

The study found that pazopanib-treated monocytes showed several changes: reduced co-stimulatory molecule expression, impaired IL-12 production, diminished T-lymphocyte stimulation, and increased expression of CD64 and ILT3. Further research found pazopanib-treated monocytes exhibited lower capacity to upregulate HLA-Dr upon LPS stimulation. These alterations collectively suggest an impaired ability of monocytes to initiate an effective anti-cancer immune response. The implications of these changes are that the use of pazopanib could impact the efficacy of DC-based cancer vaccines.

5

What are the implications of these findings for future cancer treatment strategies?

The research suggests that when designing personalized DC-based vaccines, it is crucial to consider the impact of concurrent cancer treatments like pazopanib on immune cell function. The implications mean that healthcare providers may need to consider the timing or dosage of pazopanib in conjunction with DC-based vaccines. Additional strategies might be necessary to overcome the immunosuppressive effects of pazopanib to optimize the effectiveness of immunotherapy. Further research is required to understand and mitigate the impact of pazopanib on monocyte function.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.